| 研究課題/領域番号 |
21K15680
|
|---|
| 研究機関 | 大阪大学 |
|---|
研究代表者 |
|
|---|
| 研究期間 (年度) |
2021-04-01 – 2024-03-31
|
| キーワード | Parkinson's disease / TMS / Psychosis / Pareidolia / Neurostimulation |
|---|
| 研究実績の概要 |
Completion of review of literature related to TMS and Parkinson’s disease non-motor symptoms. Completion of IRB requirements and jRCT registration (Specific clinical trial, Osaka University IRB number S21002, jRCT no: jRCTs052210061)
Number of feasibility check experiments = 5; Total number of patients satisfying eligibility criteria = 8 (as of Oct 2022); Testing completed (both Real and Sham TMS stimulation) = 3 patients. One IRB review board meeting has been completed to ascertain the progress, quality control and documentation check of CRF (Case report forms). Project related updates were discussed in 2 domestic seminars. A part of the project was also showcased for post-doctoral researchers and tenure-tracked staff in AMED-Interstellar Initiative program 2021-2022. Later this year (2023), One international seminar (with India) is planned. The evaluation protocol involves eye-tracking, EEG, and to some extent, motion capture (head motion) during testing, which is measured by separate instruments / equipment. Synchronization of these equipment is done externally and is currently being reviewed to make a single software based approach.
|
| 現在までの達成度 (区分) |
現在までの達成度 (区分)
2: おおむね順調に進展している
理由
Due to COVID protocols last year, patient recruitment were not complete. IRB and jRCT applications had to be extended and some documentation related work resulted in delay in the milestones. However, relation of rules for COVID within out-patient departments and the current status of approval has allowed speedier recruitment of patients.
|
| 今後の研究の推進方策 |
The current recruitment phase will complete data collection by end of September-October 2023.
Analysis of data will be performed simultaneously during this time.
First draft of results will be available by end of December.
Dissemination of results will be performed in 2 local and international conferences.
The efforts are focused on defining a proof-of-concept for the utilization of transcranial magnetic stimulation as therapeutic modality for hallucinatory symptoms. New funding will be solicited with respect to research and development of TMS modality in such patients.
|
| 次年度使用額が生じた理由 |
Upcoming costs include: 1) Travel expenses related to patient testing at Osaka University Hospital, 2) Publication costs for the article, 3) Conference and symposium expenses for dissemination of information, 4) Honorarium for experimenters (as part-time) for data collection (starting from Apr 2023, need basis only), and 5) From our initial experiments, the evaluation protocol involves eye-tracking, EEG, and to some extent, motion capture (head motion) during testing, which is measured by separate instruments / equipment. Synchronization of these equipment is done externally and is currently being reviewed to make a single software based approach. Development of this software is planned which will be outsourced.
|
